Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Redwood City, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The company has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The company offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Acutus Medical, Inc. ALR TECHNOLOGIES INC. REMSleep Holdings Inc Streamex Corp Delcath Systems Inc Strata Skin Sciences Inc OMNIA WELLNESS INC. NeuroMetrix, Inc. NeuroOne Medical Technologies Corp